Saturday 17 October 2026 Export IART’s income statement to Excel — free account

Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.21 0.32 −2.37%

Follow IART

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: 26.1×
Dividend yield: —
F-score: 5/9
Altman Z: 0.62
Beneish M: −3.25
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 13.89%

Capital & Financial Ratios $m

Market Cap 1,050.00

Revenue 1,647.67

Net Income (7.24)

Free Cash Flow 25.80

Net Debt 1,554.62

Current Ratio 3.60

Debt/Equity 1.75

P/E ratio 0.00

Fwd P/E 26.10

P/S ratio 0.62

P/B ratio 0.98

Past 5Y EPS Growth —

This Y EPS Growth 8.11%

Next Y EPS Growth 5.54%

Next Y revenue growth 1.27%

Next 5Y EPS Growth 7.54%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 6.49%

10-year low 10-year high

P/B against its own 10 years 9.03%

10-year low 10-year high

EV/Sales against its own 10 years 6.08%

10-year low 10-year high

EV/FCF against its own 10 years 92.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	309	274	264	274
Receivables	259	272	279	267
Inventory	390	429	493	492
Other	33	30	28	54
	1,058	1,082	1,160	1,191

	2023	2024	2025	Q'26
Payables	92	83	96	83
ST’ Debt	—	573	88	—
Other	9	10	11	12
	307	922	456	331

Compound Annual Growth %

	10y	5y	3y
Sales	6.36%	3.57%	1.63%
Cash Flow	(7.07%)	(24.39%)	(42.46%)
Earnings	0.00%	0.00%	0.00%
Book Value	3.34%	(7.18%)	(16.69%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	392	419	—	—	—
’25	383	416	402	435	1,635
’24	369	418	381	443	1,611
’23	381	381	382	397	1,542
’22	377	398	385	398	1,558
’21	360	390	387	406	1,542
’20	354	259	370	389	1,372

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	10	23	—	—	—
’25	(11)	9	41	12	50
’24	16	40	22	51	129
’23	26	28	27	59	140
’22	44	66	68	85	264
’21	69	91	83	69	312
’20	21	33	70	80	204

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	10	—	—	—
’25	(40)	(11)	26	(5)	(45)
’24	0	11	(7)	21	15
’23	12	13	14	34	73
’22	35	57	59	82	233
’21	62	85	75	42	264
’20	4	29	63	72	169

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.06)	0.06	—	—	—
’25	(0.33)	(6.31)	(0.07)	(0.02)	(6.74)
’24	(0.04)	(0.16)	(0.14)	0.25	(0.09)
’23	0.29	0.05	0.24	0.25	0.84
’22	0.39	0.54	0.60	0.63	2.16
’21	0.53	0.41	0.51	0.53	1.98
’20	0.11	0.00	0.38	1.09	1.57

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	27.38	40.51	42.33	42.14	34.21	61.85	40.67	33.44	16.81	10.87	Analyst estimates 2026–2028 Powerpack
	High	44.43	56.42	67.50	65.09	67.29	77.40	69.90	60.69	45.42	27.13
People
People	Employees	3,700	4,400	4,500	4,000	3,700	3,800	3,722	3,946	4,396	4,427
	Revenue/emp, $m	0.27	0.27	0.33	0.38	0.37	0.41	0.42	0.39	0.37	0.37
Income, $m
Income, $m	Revenue	992	1,188	1,472	1,518	1,372	1,542	1,558	1,542	1,611	1,635
	Gross margin, %	64.81	63.35	61.19	62.79	62.03	61.24	62.29	57.39	54.77	50.86
	EBT	90	11	57	60	94	215	214	81	(18)	(564)
	EBT margin, %	9.11	0.96	3.90	3.96	6.82	13.92	13.73	5.26	(1.13)	(34.46)
	Net income	75	65	61	50	134	169	181	68	(7)	(516)
	Depreciation	75	92	117	115	144	127	125	130	146	157
Per share, $
Per share, $	Revenue	13.34	15.45	17.77	17.72	16.21	18.21	18.77	19.25	20.91	21.33
	Earnings	0.94	0.82	0.72	0.58	1.57	1.98	2.16	0.84	(0.09)	(6.74)
	Cash flow	1.56	1.49	2.41	2.70	2.41	3.69	3.19	1.75	1.68	0.66
	Capex	(0.63)	(0.56)	(0.93)	(0.81)	(0.42)	(0.57)	(0.38)	(0.83)	(1.49)	(1.25)
	Free cash flow	0.93	0.93	1.48	1.89	1.99	3.12	2.81	0.91	0.19	(0.59)
	Book value	11.29	12.51	16.60	16.54	17.90	19.89	21.74	19.83	20.07	13.61
	Shares, m	74	77	83	86	85	85	83	80	77	77
Valuation, ×
Valuation, ×	P/E	46.55	57.16	62.64	100.48	41.20	33.83	25.79	52.11	0.00	0.00
	P/S	3.19	3.03	2.54	3.29	4.01	3.68	2.97	2.25	1.08	0.58
	P/B	3.77	3.75	2.72	3.52	3.63	3.37	2.56	2.18	1.13	0.91
	EV/Sales	3.76	4.40	3.35	4.05	4.77	4.36	3.61	3.06	2.01	1.53
	EV/FCF	53.81	73.22	40.32	37.99	38.83	25.42	24.11	64.52	129.88	(80.70)
Cash, $m
Cash, $m	Operating cash flow	116	115	200	231	204	312	264	140	129	50
	Capex	(47)	(43)	(77)	(69)	(35)	(48)	(31)	(67)	(114)	(96)
	Free cash flow	69	71	122	162	169	264	233	73	15	(45)
Balance, $m
Balance, $m	Working capital	372	473	513	527	836	814	841	751	160	704
	Total debt	665	1,841	1,355	1,360	1,521	1,561	1,458	1,485	1,769	1,817
	Net debt	563	1,666	1,216	1,161	1,051	1,048	1,002	1,176	1,496	1,554
	Shareholders’ equity	840	962	1,376	1,417	1,515	1,685	1,804	1,588	1,545	1,043
Returns, %
Returns, %	ROA	4.16	2.58	1.92	1.57	3.87	4.57	4.71	1.77	(0.18)	(13.52)
	ROIC	5.14	1.07	2.68	2.27	3.69	4.51	5.32	2.52	0.58	(11.87)
	ROE	9.37	7.19	5.20	3.60	9.13	10.57	10.35	3.99	(0.44)	(39.90)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TNDM Tandem Diabetes Care, Inc.	$1.2B	— (loss-making)	— (loss-making)	+5.77% (above 0%: growing)	n/m	−146.34% (below 0%: shrinking)	56.87%	(5.42%)	Compare
IRMD iRadimed Corporation	$1.1B	48.5×	48.7×	+0.28% (above 0%: growing)	−8.89% (below 0%: shrinking)	+11.66% (above 0%: growing)	74.07%	31.23%	Compare
ENOV Enovis Corporation	$1.1B	— (loss-making)	195×	+3.23% (above 0%: growing)	n/m	+815.79% (above 0%: growing)	61.64%	2.99%	Compare
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)	Compare
CBLL CeriBell, Inc.	$1.1B	— (loss-making)	— (loss-making)	+32.54% (above 0%: growing)	n/m	−68.63% (below 0%: shrinking)	92.32%	(71.11%)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
QDEL QuidelOrtho Corporation	$953.9M	— (loss-making)	— (loss-making)	+2.77% (above 0%: growing)	n/m	−61.45% (below 0%: shrinking)	43.26%	(3.46%)	Compare
Median of peers	$1.1B	—	95.4×	+6.80%	—	−42.94%	62.84%	(4.44%)

All 149 Medical Devices stocks →

Integra LifeSciences Holdings Corporation (IART) key facts

Strength: Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024.
Integra LifeSciences Holdings Corporation (IART) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IART traded at $13.21, a market capitalization of $1.1 billion.
Return on equity was −39.9% and debt-to-equity 1.75.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.62 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.